Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash-to-Debt 0.17
ALRPRB's Cash-to-Debt is ranked lower than
85% of the 227 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.44 vs. ALRPRB: 0.17 )
Ranked among companies with meaningful Cash-to-Debt only.
ALRPRB' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.08  Med: 0.14 Max: 1.88
Current: 0.17
0.08
1.88
Equity-to-Asset 0.32
ALRPRB's Equity-to-Asset is ranked lower than
84% of the 208 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.61 vs. ALRPRB: 0.32 )
Ranked among companies with meaningful Equity-to-Asset only.
ALRPRB' s Equity-to-Asset Range Over the Past 10 Years
Min: -0.49  Med: 0.35 Max: 0.77
Current: 0.32
-0.49
0.77
Debt-to-Equity 1.65
ALRPRB's Debt-to-Equity is ranked lower than
94% of the 141 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.31 vs. ALRPRB: 1.65 )
Ranked among companies with meaningful Debt-to-Equity only.
ALRPRB' s Debt-to-Equity Range Over the Past 10 Years
Min: -7.59  Med: 0.93 Max: 4.08
Current: 1.65
-7.59
4.08
Piotroski F-Score: 4
Altman Z-Score: 0.78
Beneish M-Score: -2.95
WACC vs ROIC
1.39%
-3.49%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 4/10

vs
industry
vs
history
Operating Margin % -3.00
ALRPRB's Operating Margin % is ranked lower than
55% of the 212 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.05 vs. ALRPRB: -3.00 )
Ranked among companies with meaningful Operating Margin % only.
ALRPRB' s Operating Margin % Range Over the Past 10 Years
Min: -44.13  Med: 3.88 Max: 7.6
Current: -3
-44.13
7.6
Net Margin % -10.71
ALRPRB's Net Margin % is ranked lower than
56% of the 211 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.21 vs. ALRPRB: -10.71 )
Ranked among companies with meaningful Net Margin % only.
ALRPRB' s Net Margin % Range Over the Past 10 Years
Min: -47.2  Med: -3.08 Max: 8.29
Current: -10.71
-47.2
8.29
ROE % -14.34
ALRPRB's ROE % is ranked lower than
57% of the 207 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.23 vs. ALRPRB: -14.34 )
Ranked among companies with meaningful ROE % only.
ALRPRB' s ROE % Range Over the Past 10 Years
Min: -34.13  Med: -4.53 Max: 9.2
Current: -14.34
-34.13
9.2
ROA % -4.38
ALRPRB's ROA % is ranked lower than
52% of the 228 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -1.45 vs. ALRPRB: -4.38 )
Ranked among companies with meaningful ROA % only.
ALRPRB' s ROA % Range Over the Past 10 Years
Min: -15.33  Med: -1.1 Max: 3.23
Current: -4.38
-15.33
3.23
ROC (Joel Greenblatt) % -7.21
ALRPRB's ROC (Joel Greenblatt) % is ranked lower than
52% of the 227 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.76 vs. ALRPRB: -7.21 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
ALRPRB' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -169.25  Med: 9.18 Max: 22.61
Current: -7.21
-169.25
22.61
3-Year Revenue Growth Rate -5.10
ALRPRB's 3-Year Revenue Growth Rate is ranked lower than
76% of the 156 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 5.50 vs. ALRPRB: -5.10 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
ALRPRB' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -8.6  Med: 8.2 Max: 73
Current: -5.1
-8.6
73
3-Year EBITDA Growth Rate -17.50
ALRPRB's 3-Year EBITDA Growth Rate is ranked lower than
80% of the 142 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 5.40 vs. ALRPRB: -17.50 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
ALRPRB' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -39.2  Med: 6.3 Max: 102.9
Current: -17.5
-39.2
102.9
3-Year EPS without NRI Growth Rate 23.10
ALRPRB's 3-Year EPS without NRI Growth Rate is ranked higher than
75% of the 126 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.80 vs. ALRPRB: 23.10 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
ALRPRB' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -57.2  Med: -9.3 Max: 76.1
Current: 23.1
-57.2
76.1
GuruFocus has detected 5 Warning Signs with Alere Inc $ALRPRB.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» ALRPRB's 30-Y Financials

Financials (Next Earnings Date: 2017-11-04 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q3 2016

ALRPRB Guru Trades in Q3 2016

Private Capital 4,743 sh (unchged)
Pioneer Investments 38,484 sh (unchged)
» More
Q4 2016

ALRPRB Guru Trades in Q4 2016

Pioneer Investments 38,484 sh (unchged)
Private Capital 4,438 sh (-6.43%)
» More
Q1 2017

ALRPRB Guru Trades in Q1 2017

Pioneer Investments 38,484 sh (unchged)
Private Capital 4,338 sh (-2.25%)
» More
Q2 2017

ALRPRB Guru Trades in Q2 2017

Pioneer Investments 38,484 sh (unchged)
Private Capital 4,258 sh (-1.84%)
» More
» Details

Insider Trades

Latest Guru Trades with ALRPRB

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Private Capital 2017-06-30 Reduce -1.84%$326.1 - $395.95 $ 399.005%4,258
Private Capital 2017-03-31 Reduce -2.25%$315 - $342.75 $ 399.0022%4,338
Private Capital 2016-12-31 Reduce -6.43%0.01%$292 - $354.68 $ 399.0021%4,438
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Preferred stocks of Alere Inc

SymbolPriceYieldDescription
ALRPRB399.003.013 % Conv Perp Pfd Shs Series -B-

Business Description

Industry: Medical Diagnostics & Research » Diagnostics & Research    NAICS: 334516    SIC: 3826
Compare:NAS:VWR, NAS:PRXL, NAS:PRAH, NAS:BRKR, NYSE:CRL, NAS:EXAS, NAS:INCR, NAS:NEOG, NAS:DXCM, NAS:MYGN, NYSE:BIO, NAS:FMI, NAS:AXDX, NAS:VREX, NAS:QDEL, NAS:MEDP, NYSE:PKI, NAS:GHDX, NAS:BEAT, NAS:ABAX » details
Traded in other countries:IM5.Germany,
Headquarter Location:USA
Alere Inc provides rapid diagnostics at the point of care, with a focus on cardio metabolic disease, infectious disease and toxicology. The Company's business segments are professional diagnostics, consumer diagnostics, and corporate and other.

Alere develops rapid point-of-care diagnostic devices in cardiology, infectious disease, toxicology, diabetes, oncology, and women's health. North America accounts for the largest portion of the firm's revenue (55%), followed by Europe (19%), Asia-Pacific (14%), and the rest of the world (12%). Alere's headquarters are in Waltham, Massachusetts.

Top Ranked Articles about Alere Inc

Alere Inc. Declares Cash Dividend on its Series B Convertible Perpetual Preferred Stock
Alere Announces Intent to Voluntarily Delist Series B Convertible Perpetual Preferred Stock from the NYSE Conditioned Upon the Completion of its Acquisition by Abbott
ALERE INVESTIGATION INITIATED BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Alere Inc. - ALR
Preferred Stock Purchase Offer Extended Abbott Labs needs extra time to complete the merger with Alere
Abbott Laboratories (NYSE:ABT) informed the market through the PR Newswire Monday that it has extended its offer to buy all of Alere Inc.'s (NYSE:ALR) preferred stock. Read more...
Alere Provides Notice to Holders of Series B Convertible Perpetual Preferred Stock
Alere Reports 2nd Quarter Company posts $92.7 million net loss
Alere Inc. (NYSE:ALR), the diagnostic tests manufacturer being acquired by Abbott Laboratories (NYSE:ABT) for $5.3 billion, delivered its financial results for the second quarter of 2017 on Aug. 3. Read more...
Immunalysis Receives FDA Clearance for SEFRIA™ Fentanyl Urine Drug Screening Test
Alere Launches Alere iCup® Rx Drug Screen for Detecting Commonly Misused and Abused Prescription Drugs
Abbott Labs Places Tender Offer for Alere's Preferred Stock The company will pay $402 per share
Abbott Laboratories (NYSE:ABT) announced July 17 it is offering to buy all of Alere Inc.'s (NYSE:ALR) preferred stockRead more...
Shareholders Approve Alere, Abbott Merger The deal is valued at $5.3 billion
Alere Inc. (NYSE:ALR) announced July 7 that its shareholders, who hold approximately 72.5% of the company’s total volume of outstanding shares, approved the amended merger deal with Abbott Laboratories (NYSE:ABT). Read more...

Ratios

vs
industry
vs
history
Price-to-Owner-Earnings 301.58
ALRPRB's Price-to-Owner-Earnings is ranked higher than
60% of the 68 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 31.54 vs. ALRPRB: 301.58 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
ALRPRB' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 9.13  Med: 23.41 Max: 3107.86
Current: 301.58
9.13
3107.86
PB Ratio 3.77
ALRPRB's PB Ratio is ranked higher than
53% of the 204 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.89 vs. ALRPRB: 3.77 )
Ranked among companies with meaningful PB Ratio only.
ALRPRB' s PB Ratio Range Over the Past 10 Years
Min: 0.42  Med: 1.76 Max: 3.83
Current: 3.77
0.42
3.83
PS Ratio 1.86
ALRPRB's PS Ratio is ranked higher than
77% of the 206 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.65 vs. ALRPRB: 1.86 )
Ranked among companies with meaningful PS Ratio only.
ALRPRB' s PS Ratio Range Over the Past 10 Years
Min: 0.52  Med: 1.43 Max: 4.22
Current: 1.86
0.52
4.22
Price-to-Free-Cash-Flow 128.58
ALRPRB's Price-to-Free-Cash-Flow is ranked higher than
53% of the 78 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 25.07 vs. ALRPRB: 128.58 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
ALRPRB' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 7.03  Med: 20.21 Max: 168.64
Current: 128.58
7.03
168.64
Price-to-Operating-Cash-Flow 46.46
ALRPRB's Price-to-Operating-Cash-Flow is ranked higher than
57% of the 90 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 20.14 vs. ALRPRB: 46.46 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
ALRPRB' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 4.63  Med: 12.04 Max: 130
Current: 46.46
4.63
130
EV-to-EBIT -136.42
ALRPRB's EV-to-EBIT is ranked lower than
99.99% of the 115 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9999.00 vs. ALRPRB: -136.42 )
Ranked among companies with meaningful EV-to-EBIT only.
ALRPRB' s EV-to-EBIT Range Over the Past 10 Years
Min: -676  Med: 46.95 Max: 683.2
Current: -136.42
-676
683.2
EV-to-EBITDA 34.75
ALRPRB's EV-to-EBITDA is ranked lower than
70% of the 126 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 19.58 vs. ALRPRB: 34.75 )
Ranked among companies with meaningful EV-to-EBITDA only.
ALRPRB' s EV-to-EBITDA Range Over the Past 10 Years
Min: -173.6  Med: 13.9 Max: 87.3
Current: 34.75
-173.6
87.3
EV-to-Revenue 3.17
ALRPRB's EV-to-Revenue is ranked higher than
64% of the 211 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.97 vs. ALRPRB: 3.17 )
Ranked among companies with meaningful EV-to-Revenue only.
ALRPRB' s EV-to-Revenue Range Over the Past 10 Years
Min: 2  Med: 2.8 Max: 6.1
Current: 3.17
2
6.1
Current Ratio 2.04
ALRPRB's Current Ratio is ranked lower than
58% of the 227 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.73 vs. ALRPRB: 2.04 )
Ranked among companies with meaningful Current Ratio only.
ALRPRB' s Current Ratio Range Over the Past 10 Years
Min: 0.7  Med: 1.78 Max: 3.42
Current: 2.04
0.7
3.42
Quick Ratio 1.54
ALRPRB's Quick Ratio is ranked lower than
62% of the 227 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.17 vs. ALRPRB: 1.54 )
Ranked among companies with meaningful Quick Ratio only.
ALRPRB' s Quick Ratio Range Over the Past 10 Years
Min: 0.46  Med: 1.36 Max: 2.89
Current: 1.54
0.46
2.89
Days Inventory 95.83
ALRPRB's Days Inventory is ranked lower than
57% of the 180 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 80.72 vs. ALRPRB: 95.83 )
Ranked among companies with meaningful Days Inventory only.
ALRPRB' s Days Inventory Range Over the Past 10 Years
Min: 80.56  Med: 93.18 Max: 104.46
Current: 95.83
80.56
104.46
Days Sales Outstanding 59.13
ALRPRB's Days Sales Outstanding is ranked higher than
52% of the 185 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 60.84 vs. ALRPRB: 59.13 )
Ranked among companies with meaningful Days Sales Outstanding only.
ALRPRB' s Days Sales Outstanding Range Over the Past 10 Years
Min: 59.13  Med: 67.28 Max: 79.93
Current: 59.13
59.13
79.93
Days Payable 65.70
ALRPRB's Days Payable is ranked higher than
54% of the 179 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 57.91 vs. ALRPRB: 65.70 )
Ranked among companies with meaningful Days Payable only.
ALRPRB' s Days Payable Range Over the Past 10 Years
Min: 45.36  Med: 53.06 Max: 65.7
Current: 65.7
45.36
65.7

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield % 3.01
ALRPRB's Dividend Yield % is ranked lower than
99.99% of the 103 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.94 vs. ALRPRB: 3.01 )
Ranked among companies with meaningful Dividend Yield % only.
ALRPRB' s Dividend Yield % Range Over the Past 10 Years
Min: 0  Med: 0 Max: 4.66
Current: 3.01
0
4.66
Forward Dividend Yield % 3.01
ALRPRB's Forward Dividend Yield % is ranked lower than
99.99% of the 99 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.11 vs. ALRPRB: 3.01 )
Ranked among companies with meaningful Forward Dividend Yield % only.
N/A
5-Year Yield-on-Cost % 3.01
ALRPRB's 5-Year Yield-on-Cost % is ranked lower than
85% of the 122 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.46 vs. ALRPRB: 3.01 )
Ranked among companies with meaningful 5-Year Yield-on-Cost % only.
ALRPRB' s 5-Year Yield-on-Cost % Range Over the Past 10 Years
Min: 0  Med: 0 Max: 4.66
Current: 3.01
0
4.66
3-Year Average Share Buyback Ratio -2.00
ALRPRB's 3-Year Average Share Buyback Ratio is ranked higher than
68% of the 146 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -6.50 vs. ALRPRB: -2.00 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
ALRPRB' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -60.8  Med: -3.4 Max: 19.3
Current: -2
-60.8
19.3

Valuation & Return

vs
industry
vs
history
Earnings Yield (Greenblatt) % -0.73
ALRPRB's Earnings Yield (Greenblatt) % is ranked higher than
50% of the 230 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.04 vs. ALRPRB: -0.73 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
ALRPRB' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -19.4  Med: 1.2 Max: 3.1
Current: -0.73
-19.4
3.1
Forward Rate of Return (Yacktman) % -7.09
ALRPRB's Forward Rate of Return (Yacktman) % is ranked lower than
78% of the 65 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 6.57 vs. ALRPRB: -7.09 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.
ALRPRB' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: -7.1  Med: 3 Max: 10.8
Current: -7.09
-7.1
10.8

More Statistics

Beta0.07
Short Percentage of Float0.00%
52-Week Range $292.00 - 400.00

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}